Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males

Lund University

Status: Completed

Conditions: Hypogonadism, Male

Treatments: Drug: GnRH antagonist

Study type: Interventional

Funder types: Other

Identifiers

NCT03541395

TP 001

Details and patient eligibility

About

The study is designed to identify and validate new protein biomarkers in blood related to testosterone activity. Thirty healthy young males underwent pharmaceutical castration to lower testosterone levels. After three weeks the subjects received an intramuscular injection of testosterone undecanoate. Blood samples from just before pharmaceutical castration, three weeks after castration, and one week after injection of testosterone undecanoate were collected representing normal testosterone levels, low testosterone levels, and testosterone at eugonadal levels.

Enrollment: 30 patients

Sex: Male

Ages: 20 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

healthy males

Exclusion criteria

use of anabolic steroids, use of narcotics,

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Testosterone

Other group

Description:

A Gonadotropin releasing hormone agonist (GnRH-agonist) is administered to lower the testosterone to castration levels. After four weeks testosterone undecanoate is administered to increase the testosterone to normal levels.

Treatment:

Drug: GnRH antagonist